Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently conducting a Phase 2 clinical study titled A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of ABBV-CLS-628 in Adult Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD). The study aims to assess the safety and effectiveness of the investigational drug ABBV-CLS-628 for treating ADPKD, a common genetic kidney disease characterized by fluid-filled cysts.
The intervention being tested is ABBV-CLS-628, administered via intravenous infusions. The study involves four groups, with three receiving different doses of ABBV-CLS-628 and one receiving a placebo, to evaluate the drug’s impact on the disease.
This randomized, parallel-assignment study employs a quadruple-masking approach, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocations. The primary goal is to determine the treatment’s efficacy and safety.
The study began on June 9, 2025, with recruitment currently ongoing. The primary completion and estimated study completion dates have not been disclosed, but the last update was submitted on July 21, 2025.
The outcome of this study could significantly influence AbbVie’s stock performance and investor sentiment, especially if the results demonstrate a breakthrough in ADPKD treatment. This could also impact the competitive landscape, as other companies in the kidney disease treatment market may be affected.
The study is ongoing, with further details available on the ClinicalTrials portal.